ReviewExperimental biology and medicine (Maywood, N.J.)2026
Nicotinamide adenine dinucleotide phosphate oxidase 4 in lung disease: a review of its biology and therapeutic potential.
Review in Experimental biology and medicine (Maywood, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) is a constitutively active enzyme that primarily produces hydrogen peroxide, a reactive oxygen species (ROS) with diverse cellular functions. While initially recognized for its role in oxidative stress, emerging evidence suggests that NOX4 plays a pivotal role in the pathogenesis of various lung diseases. This review delineates the structure characteristics of NOX4, emphasizing how its domain organization underlies a distinctive mode of molecular regulation. It further discusses current knowledge on the biological functions of NOX4-derived oxygen species, including their roles in modulating inflammation, cell death pathways, oxygen sensing, nuclear signaling, and metabolic reprogramming. Through these interconnected processes, NOX4 is positioned as a central mediator linking redox imbalance to cellular dysfunction. In addition, the contribution of NOX4 to the pathogenesis of major lung diseases, including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), asthma, acute lung injury/acute respiratory distress syndrome (ALI/ARDS), and pulmonary hypertension are critically evaluated. Emerging therapeutic strategies targeting NOX4 are also discussed, together with key challenges associated with clinical translation, including isoform specificity, off-target effects, and tissue-selective delivery. Overall, this review provides an integrated framework for understanding NOX4 biology across multiple levels and highlights its potential as a therapeutic target in lung disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.